ES2755093T3 - Inhibidores del extremo C-terminal de Hsp90 - Google Patents
Inhibidores del extremo C-terminal de Hsp90 Download PDFInfo
- Publication number
- ES2755093T3 ES2755093T3 ES13706822T ES13706822T ES2755093T3 ES 2755093 T3 ES2755093 T3 ES 2755093T3 ES 13706822 T ES13706822 T ES 13706822T ES 13706822 T ES13706822 T ES 13706822T ES 2755093 T3 ES2755093 T3 ES 2755093T3
- Authority
- ES
- Spain
- Prior art keywords
- acetamide
- oxy
- methoxy
- ethyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC*C(*(*)*C)Oc1cc(-c(c**(*)c2*)c2I)c(*)cc1 Chemical compound CC*C(*(*)*C)Oc1cc(-c(c**(*)c2*)c2I)c(*)cc1 0.000 description 3
- IUNJCFABHJZSKB-UHFFFAOYSA-N Oc1ccc(C=O)c(O)c1 Chemical compound Oc1ccc(C=O)c(O)c1 IUNJCFABHJZSKB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597004P | 2012-02-09 | 2012-02-09 | |
| PCT/US2013/025387 WO2013119985A1 (en) | 2012-02-09 | 2013-02-08 | C-terminal hsp90 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2755093T3 true ES2755093T3 (es) | 2020-04-21 |
Family
ID=47754998
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13706822T Active ES2755093T3 (es) | 2012-02-09 | 2013-02-08 | Inhibidores del extremo C-terminal de Hsp90 |
| ES19193576T Active ES2974721T3 (es) | 2012-02-09 | 2013-02-08 | Intermedios para la preparación de inhibidores del extremo C-terminal de Hsp90 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19193576T Active ES2974721T3 (es) | 2012-02-09 | 2013-02-08 | Intermedios para la preparación de inhibidores del extremo C-terminal de Hsp90 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US9422320B2 (enExample) |
| EP (3) | EP3656758B1 (enExample) |
| JP (1) | JP6121450B2 (enExample) |
| KR (1) | KR102124109B1 (enExample) |
| CN (2) | CN104271587B (enExample) |
| AU (1) | AU2013216858C1 (enExample) |
| BR (1) | BR112014019704B1 (enExample) |
| CA (1) | CA2866814C (enExample) |
| CY (1) | CY1122358T1 (enExample) |
| DK (2) | DK2812341T3 (enExample) |
| EA (1) | EA027147B1 (enExample) |
| ES (2) | ES2755093T3 (enExample) |
| FI (1) | FI3656758T3 (enExample) |
| HR (2) | HRP20240514T1 (enExample) |
| HU (2) | HUE046939T2 (enExample) |
| LT (2) | LT3656758T (enExample) |
| MX (1) | MX361233B (enExample) |
| NZ (1) | NZ629778A (enExample) |
| PL (2) | PL2812341T3 (enExample) |
| PT (2) | PT2812341T (enExample) |
| RS (2) | RS65412B1 (enExample) |
| SI (2) | SI3656758T1 (enExample) |
| SM (2) | SMT201900660T1 (enExample) |
| WO (1) | WO2013119985A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014019704B1 (pt) | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| EP3154964B1 (en) | 2014-06-13 | 2023-04-05 | The University of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| MX388515B (es) * | 2014-06-24 | 2025-03-20 | Univ Kansas | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. |
| WO2016145219A1 (en) * | 2015-03-10 | 2016-09-15 | University Of Florida Research Foundation, Inc. | Treatment of peripheral neuropathies |
| US20210036245A1 (en) * | 2017-12-20 | 2021-02-04 | Merck Patent Gmbh | Heteroaromatic compounds |
| MX2020008326A (es) * | 2018-02-07 | 2020-09-28 | Reata Pharmaceuticals Inc | Formas de co-cristales de un analogo de novobiocina y prolina. |
| EP3794009A1 (en) * | 2018-05-14 | 2021-03-24 | Reata Pharmaceuticals, Inc. | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608594B2 (en) | 2004-11-03 | 2009-10-27 | University Of Kansas | Novobiocin analogues as anticancer agents |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| WO2007095586A2 (en) * | 2006-02-14 | 2007-08-23 | The Trustees Of Columbia University In The City Of New York | Neuronal pain pathway modulators |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US8044041B2 (en) | 2006-11-15 | 2011-10-25 | Forest Laboratories Holdings Limited | Phthalazine derivatives as inhibitors of protein kinase |
| EA019103B1 (ru) | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| JP5766617B2 (ja) | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
| WO2011041593A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| CN101967125B (zh) * | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
| CA2832099C (en) | 2011-04-05 | 2019-07-09 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| US9056104B2 (en) | 2011-05-20 | 2015-06-16 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| BR112014019704B1 (pt) | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| AU2014346483B2 (en) | 2013-11-07 | 2019-01-17 | The University Of Kansas | Biphenylamide derivative Hsp90 inhibitors |
| EP3068778B1 (en) | 2013-11-11 | 2025-02-19 | The University of Kansas | Coumarin based hsp90 inhibitors with urea and ether substituents |
| EP3154964B1 (en) | 2014-06-13 | 2023-04-05 | The University of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| MX388515B (es) | 2014-06-24 | 2025-03-20 | Univ Kansas | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. |
| EP3794009A1 (en) | 2018-05-14 | 2021-03-24 | Reata Pharmaceuticals, Inc. | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
-
2013
- 2013-02-08 BR BR112014019704-0A patent/BR112014019704B1/pt active IP Right Grant
- 2013-02-08 PT PT137068227T patent/PT2812341T/pt unknown
- 2013-02-08 EP EP19193576.6A patent/EP3656758B1/en active Active
- 2013-02-08 DK DK13706822T patent/DK2812341T3/da active
- 2013-02-08 SM SM20190660T patent/SMT201900660T1/it unknown
- 2013-02-08 PL PL13706822T patent/PL2812341T3/pl unknown
- 2013-02-08 SI SI201332079T patent/SI3656758T1/sl unknown
- 2013-02-08 HU HUE13706822A patent/HUE046939T2/hu unknown
- 2013-02-08 HU HUE19193576A patent/HUE066259T2/hu unknown
- 2013-02-08 RS RS20240452A patent/RS65412B1/sr unknown
- 2013-02-08 NZ NZ629778A patent/NZ629778A/en unknown
- 2013-02-08 US US14/377,616 patent/US9422320B2/en active Active
- 2013-02-08 MX MX2014009608A patent/MX361233B/es active IP Right Grant
- 2013-02-08 WO PCT/US2013/025387 patent/WO2013119985A1/en not_active Ceased
- 2013-02-08 RS RS20191454A patent/RS59719B1/sr unknown
- 2013-02-08 EP EP24161059.1A patent/EP4403552A3/en active Pending
- 2013-02-08 PL PL19193576.6T patent/PL3656758T3/pl unknown
- 2013-02-08 JP JP2014556739A patent/JP6121450B2/ja active Active
- 2013-02-08 SI SI201331622T patent/SI2812341T1/sl unknown
- 2013-02-08 CN CN201380019057.XA patent/CN104271587B/zh active Active
- 2013-02-08 AU AU2013216858A patent/AU2013216858C1/en active Active
- 2013-02-08 CN CN201710729038.6A patent/CN107474085B/zh active Active
- 2013-02-08 HR HRP20240514TT patent/HRP20240514T1/hr unknown
- 2013-02-08 KR KR1020147025348A patent/KR102124109B1/ko active Active
- 2013-02-08 EP EP13706822.7A patent/EP2812341B1/en active Active
- 2013-02-08 EA EA201491496A patent/EA027147B1/ru unknown
- 2013-02-08 SM SM20240145T patent/SMT202400145T1/it unknown
- 2013-02-08 DK DK19193576.6T patent/DK3656758T3/da active
- 2013-02-08 LT LTEP19193576.6T patent/LT3656758T/lt unknown
- 2013-02-08 LT LT13706822T patent/LT2812341T/lt unknown
- 2013-02-08 HR HRP20191940TT patent/HRP20191940T1/hr unknown
- 2013-02-08 ES ES13706822T patent/ES2755093T3/es active Active
- 2013-02-08 ES ES19193576T patent/ES2974721T3/es active Active
- 2013-02-08 FI FIEP19193576.6T patent/FI3656758T3/fi active
- 2013-02-08 PT PT191935766T patent/PT3656758T/pt unknown
- 2013-02-08 CA CA2866814A patent/CA2866814C/en active Active
-
2016
- 2016-08-03 US US15/227,230 patent/US10030041B2/en active Active
-
2018
- 2018-06-26 US US16/018,401 patent/US10590157B2/en active Active
-
2019
- 2019-11-11 CY CY20191101180T patent/CY1122358T1/el unknown
-
2020
- 2020-02-05 US US16/783,025 patent/US10882881B2/en active Active
- 2020-12-04 US US17/112,060 patent/US11390640B2/en active Active
-
2022
- 2022-07-12 US US17/863,135 patent/US12024536B2/en active Active
-
2024
- 2024-05-17 US US18/667,496 patent/US20240417419A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2755093T3 (es) | Inhibidores del extremo C-terminal de Hsp90 | |
| US7250522B2 (en) | Method for selective preparation of aryl 5-thio-β-D-aldohexopyranosides | |
| JPWO2008016132A1 (ja) | ベンジルフェニルグルコピラノシド誘導体 | |
| CA2869416A1 (en) | Mannose derivatives for treating bacterial infections | |
| US20090182133A1 (en) | Benzopyranone derivatives and their use as anti-viral agents | |
| HK1249519B (zh) | Hsp90 c端抑制剂及其医药组合物和用途 | |
| HK1205131B (en) | C-terminal hsp90 inhibitors | |
| CN120398981A (zh) | 具有HIF-1α蛋白抑制活性的红景天苷衍生物及其合成和应用 |